Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | CD44 | P16070 | 1/20 | 0.34 |
| ▸ | NOS3 | P29474 | 3/20 | 0.34 |
| ▸ | NOS2 | P35228 | 3/20 | 0.34 |
| ▸ | NOS1 | P29475 | 2/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | CASP1 | P29466 | 1/20 | 0.33 |
| ▸ | CASP7 | P55210 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 2/20 | 0.32 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1293277 | 0.83 | GABRA1 (0.48) | GABRA1GABRB2TSHRALDH1A1HSD17B10 | |
| SCHEMBL434493 | 0.83 | CYP3A4 (0.48) | GABRA1GABRB2CYP3A4TSHRPIK3CA | |
| SCHEMBL27667624 | 0.79 | MEN1 (0.35) | GABRA1GABRB2ALDH1A1HSD17B10NOS3 | |
| SCHEMBL30937520 | 0.79 | TAAR1 (0.37) | CYP3A4TSHRPIK3CAALDH1A1TDP1 | |
| SCHEMBL14253791 | 0.79 | CYP3A4 (0.36) | CYP3A4TSHRPIK3CAALDH1A1TDP1 | |
| SCHEMBL8467859 | 0.79 | NOS3 (0.33) | GABRA1GABRB2CYP3A4TSHRALDH1A1 | |
| SCHEMBL1398159 | 0.79 | TAAR1 (0.37) | CYP3A4TSHRPIK3CAALDH1A1TDP1 | |
| SCHEMBL18184983 | 0.78 | ALDH1A1 (0.37) | CYP3A4TSHRPIK3CAALDH1A1HPGD | |
| SCHEMBL29037467 | 0.77 | CYP3A4 (0.35) | CYP3A4TSHRPIK3CAALDH1A1TDP1 | |
| SCHEMBL1372190 | 0.77 | GABRA1 (0.35) | GABRA1CYP3A4TSHRPIK3CAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637435-B2 | Nitrogen-containing heterocyclic compound or salt thereof, use thereof, and intermediate thereof | FUJIFILM CORPORATION (JP) | 2026-05-26 | — | — | US | disclosed |
| US-12421217-B2 | Pyrazine derivative or salt thereof, and use of same | FUJIFILM CORPORATION (JP) | 2025-09-23 | — | — | US | disclosed |
| EP-4190402-B1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND OR SALT THEREOF, USE THEREOF, AND INTERMEDIATE THEREOF | FUJIFILM CORP (JP) | 2025-08-27 | — | — | EP | disclosed |
| EP-4052760-B1 | PYRAZINE DERIVATIVE OR SALT THEREOF, AND USE OF SAME | FUJIFILM CORP (JP) | 2024-03-13 | — | — | EP | disclosed |
| US-20240025878-A1 | MDM2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20230303526-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-09-28 | — | — | US | disclosed |
| US-20230257380-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN (SHANGHAI), INC. (CN) | 2023-08-17 | — | — | US | disclosed |
| US-20230250110-A1 | DEUTERATED IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-08-10 | — | — | US | disclosed |
| US-20230234953-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-07-27 | — | — | US | disclosed |
| US-11685750-B2 | Crystalline forms of IRAK degraders | KYMERA THERAPEUTICS, INC. (US) | 2023-06-27 | — | — | US | disclosed |
| WO-2004047739-A2 | PYRIDINYL, PYRIMIDINYL AND PYRAZINYL AMIDES AS POTASSIUM CHANNEL OPENERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-06-10 | — | — | WO | disclosed |
| US-20040102449-A1 | Pyridinyl, pyrimidinyl and pyrazinyl amides as potassium channel openers | BRISTOL-MYERS SQUIBB COMPANY | 2004-05-27 | — | — | US | disclosed |
| US-20030166650-A1 | Cinnamide derivatives as KCNQ potassium channel modulators | BRISTOL-MYERS SQUIBB COMPANY | 2003-09-04 | — | — | US | disclosed |
| EP-0294685-B1 | Process for the preparation of quinolines | BASF AG (DE) | 1995-08-02 | — | — | EP | disclosed |
| CN-1028170-C | Process for preparing quinoline | BASF AG (DE) | 1995-04-12 | — | — | CN | disclosed |
| CN-1030231-A | The preparation method of quinoline | BASF AG (DE) | 1989-01-11 | — | — | CN | disclosed |
| EP-0294685-A2 | Process for the preparation of quinolines | BASF Aktiengesellschaft (DE) | 1988-12-14 | — | — | EP | disclosed |
| US-3948950-A | HERBICIDES | VELSICOL CHEMICAL CORPORATION (US) | 1976-04-06 | — | — | US | disclosed |
| US-3942972-A | Dioxolane substituted α-haloanilides as herbicides | VELSICOL CHEMICAL CORPORATION (US) | 1976-03-09 | — | — | US | disclosed |
| US-3940259-A | Dioxane substituted-α-haloanilides as herbicides | VELSICOL CHEMICAL CORPORATION (US) | 1976-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257380-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | MUSK, ERBB2, NTRK1 | GABRA1 1248/4885GABRB2 774/4885CYP3A4 4645/4885 |
| US-20040102449-A1 | Pyridinyl, pyrimidinyl and pyrazinyl amides as potassium channel openers | KCNQ5, KCNQ2, KCNQ3 | GABRA1 140/4885GABRB2 126/4885CYP3A4 564/4885 |
| US-20240025878-A1 | MDM2 DEGRADERS AND USES THEREOF | MDM2, TP53, MDM4 | GABRA1 4152/4885GABRB2 4357/4885CYP3A4 1072/4885 |
| US-20230234953-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | GABRA1 2928/4885GABRB2 3421/4885CYP3A4 2542/4885 |
| US-20030166650-A1 | Cinnamide derivatives as KCNQ potassium channel modulators | KCNH2, KCNH3, KCNQ1 | GABRA1 512/4885GABRB2 358/4885CYP3A4 543/4885 |
| US-11685750-B2 | Crystalline forms of IRAK degraders | IRAK1, IRAK2, IRAK4 | GABRA1 3192/4885GABRB2 3414/4885CYP3A4 4431/4885 |
| US-12421217-B2 | Pyrazine derivative or salt thereof, and use of same | DHODH, IDH1, IDH2 | GABRA1 4526/4885GABRB2 4530/4885CYP3A4 1097/4885 |
| US-12637435-B2 | Nitrogen-containing heterocyclic compound or salt thereof, use thereof, and intermediate thereof | CBR1, DHODH, CBR3 | GABRA1 3535/4885GABRB2 3293/4885CYP3A4 1397/4885 |
| US-20230303526-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | GABRA1 2928/4885GABRB2 3421/4885CYP3A4 2542/4885 |
| US-20230250110-A1 | DEUTERATED IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | GABRA1 3840/4885GABRB2 4397/4885CYP3A4 3567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.